Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 30
- Registration Number
- NCT05715931
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Ningbo First Hospital, Ningbo, Zhejiang, China
🇨🇳Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT05672524
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Shanghai Pudong Hospital
- Target Recruit Count
- 204
- Registration Number
- NCT05656079
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT05638594
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Personalized Medicine for Advanced Biliary Cancer Patients
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 800
- Registration Number
- NCT05615818
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven, Leuven, Belgium
🇫🇷CHU Amiens Picardie, Amiens, France
🇫🇷CHU d'Angers, Angers, France
RP-6306 in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 78
- Registration Number
- NCT05605509
- Locations
- 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦BCCA - Kelowna, Kelowna, British Columbia, Canada
🇨🇦BCCA - Vancouver, Vancouver, British Columbia, Canada
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 49
- Registration Number
- NCT05583110
- Locations
- 🇪🇸
Complejo hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Las Palmas, Spain
🇪🇸Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 126
- Registration Number
- NCT05577923
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 72
- Registration Number
- NCT05574881
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.